Communication, collaboration and transparency between sites and sponsors mean trials start up and close out faster.
In rare disease research, every patient is precious. Read how the IQVIA Investigator Site Portal enables Alnylam Pharmaceutical’s patient-centered and site-first approach, which has delivered four approved products in the last two years and created an entirely new class of medications known as RNAi therapeutics.
Communication, collaboration and transparency between sites and sponsors mean trials start up and close out faster.
Increase transparency, improve communications and reduce administrative burden for all clinical trial stakeholders.
Ease the burden on your sites and make it easier and more appealing for patients to enroll and remain engaged.
Combine data science, technology, and analytics driven by artificial intelligence to support new efficiencies and business insights -- without additional capital investment.